jakavi 15mg tablet - Ruxolitinib (15mg) medicine

Jakavi 15mg Tablet: Comprehensive Guide to Uses, Side Effects, and Safety

No reviews yet
🏭 Novartis India Ltd 📦 Varies by brand 💊 Allopathy 📅 Updated: Sep 26, 2026
📋 Prescription Required 💊 Generic Available
Medically Reviewed
11 min read
Evidence: High
Reviewed by
SaathiMed Expert Panel | Sep 26, 2026
🩺
Medically Fact-Checked & Clinically Verified by SaathiMed Clinical Review Board
Clinical Reference Standards: CDSCO (Central Drugs Standard Control Organisation), Indian Pharmacopoeia (IP) & WHO | Last Updated: September 2026

When to Call Your Doctor IMMEDIATELY

  • Fever, chills, or persistent cough that may indicate a serious infection.
  • Unusual bleeding or bruising, such as nosebleeds, gum bleeding, or blood in stool.
  • Sudden confusion, memory loss, difficulty walking, or vision changes that could signal PML.
  • Yellowing of the skin or eyes, dark urine, or severe abdominal pain indicating liver problems.
  • Swelling of the face, lips, tongue, or throat, or difficulty breathing suggesting an allergic reaction.
  • Chest pain, shortness of breath, or rapid heartbeat that may indicate a cardiac event.
  • Decreased urine output or swelling in the legs that could indicate kidney problems.
  • Severe headache, dizziness, or fainting that may be due to low blood pressure.

If experiencing severe symptoms, call emergency services immediately.

What is jakavi 15mg tablet used for?

This medicine is a JAK inhibitor used to treat myelofibrosis, polycythemia vera, and graft-versus-host disease. It works by blocking JAK1 and JAK2 enzymes, reducing abnormal blood cell production and inflammation. It is taken orally, usually twice daily, and requires regular blood tests to monitor for side effects.

  • Generic Name: Ruxolitinib (15mg)
  • Manufacturer: Novartis India Ltd
  • Form: Allopathy
  • Pregnancy Category: Consult doctor
  • Prescription Required: Yes

🇮🇳 jakavi 15mg tablet के बारे में (Hindi Summary)

उपयोग: यह दवा मायलोफाइब्रोसिस, पॉलीसिथेमिया वेरा और ग्राफ्ट-वर्सेस-होस्ट डिजीज के इलाज के लिए इस्तेमाल की जाती है। यह जेएके1 और जेएके2 एंजाइम को ब्लॉक करके काम करती है, जिससे असामान्य रक्त कोशिका उत्पादन और सूजन कम होती है। यह तिल्ली के आकार को कम करने, खुजली, रात के पसीने और थकान जैसे लक्षणों से राहत देने में मदद करती है। यह दवा मुँह से ली जाती है और आमतौर पर दिन में दो बार लेनी होती है। इसका सेवन डॉक्टर की सलाह के अनुसार ही करें।

साइड इफेक्ट्स: आम दुष्प्रभावों में चक्कर आना, सिरदर्द, थकान, और रक्त कोशिकाओं की कमी (एनीमिया, थ्रोम्बोसाइटोपेनिया, न्यूट्रोपेनिया) शामिल हैं। गंभीर दुष्प्रभावों में गंभीर संक्रमण, प्रगतिशील मल्टीफोकल ल्यूकोएन्सेफैलोपैथी (पीएमएल), और लिम्फोमा शामिल हैं। यदि आपको बुखार, असामान्य रक्तस्राव, या तंत्रिका संबंधी लक्षण दिखाई दें तो तुरंत डॉक्टर से संपर्क करें।

सुरक्षा सलाह: इस दवा को डॉक्टर के बताए अनुसार ही लें। बिना सलाह के दवा बंद या डोज न बदलें। नियमित रक्त परीक्षण करवाते रहें। संक्रमण से बचने के लिए भीड़-भाड़ वाली जगहों से बचें। गर्भावस्था के दौरान इस दवा का सेवन न करें। ग्रेपफ्रूट और ग्रेपफ्रूट जूस से बचें। यदि आपको कोई संक्रमण, असामान्य रक्तस्राव, या तंत्रिका संबंधी समस्या हो तो तुरंत डॉक्टर को बताएं।

💡 Did You Know? The Indian pharmaceutical market is expected to reach $130 billion by 2030.

💊 jakavi 15mg tablet Uses & Benefits

  • [{"condition":"Myelofibrosis","description":"This medicine is indicated for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis.
  • It helps reduce spleen size and alleviate symptoms such as abdominal discomfort, night sweats, itching, and bone pain.","evidence":"Well-established"},{"condition":"Polycythemia Vera","description":"This medicine is used for the treatment of polycythemia vera in patients who have had an inadequate response to or are intolerant of hydroxyurea.
  • It helps control blood counts and reduce the risk of thrombotic events.","evidence":"Well-established"},{"condition":"Graft-versus-Host Disease","description":"This medicine is indicated for the treatment of steroid-refractory acute graft-versus-host disease in patients aged 12 years and older.
  • It helps manage inflammation and improve survival.","evidence":"Well-established"}]

Off-label uses: [{"condition":"Alopecia Areata","description":"This medicine has been studied off-label for severe alopecia areata, showing potential to promote hair regrowth. However, it is not approved for this indication.","evidence":"Limited"},{"condition":"Atopic Dermatitis","description":"Topical formulations of ruxolitinib are approved for atopic dermatitis, but oral use is off-label and not recommended without specialist guidance.","evidence":"Limited"}]

Primary treatment for: Myelofibrosis

Also treats: Polycythemia Vera, Graft-versus-Host Disease

📋 Drug Information

Generic Name(s)Ruxolitinib (15mg)
Brand Namejakavi 15mg tablet
ManufacturerNovartis India Ltd
Packaging / FormVaries by brand (Allopathy)
Therapeutic ClassANTI NEOPLASTICS
Action ClassTyrosine kinase inhibitors
Route of AdministrationOral
StorageStore at room temperature between 20°C and 25°C (68°F to 77°F). Keep in the original container, tightly closed, away from moisture and heat. Do not refrigerate. Keep out of reach of children.
Shelf Life24 months from the date of manufacture.
WHO GuidelineNot established from the available information.
ICMR GuidelineNot established from the available information.

👨‍⚕️ Doctor's Practical Tips

Evidence-based practical advice from experienced clinicians

1
Always check complete blood counts before starting and regularly during treatment with this medicine.
2
Screen for hepatitis B and tuberculosis before initiating therapy to prevent reactivation.
3
Adjust the dose based on platelet counts, renal and hepatic function, and concomitant medications.
4
Warn patients about the risk of serious infections and advise them to report early symptoms.
5
Avoid concomitant use with strong CYP3A4 inhibitors or inducers; if unavoidable, adjust the dose of this medicine.
6
Monitor for signs of progressive multifocal leukoencephalopathy (PML) and other neurological symptoms.
7
Advise patients to use effective contraception during treatment and for at least 2 weeks after the last dose.
8
Do not administer live vaccines during treatment.
9
Educate patients about the importance of not stopping the medicine abruptly.
10
Regularly assess spleen size and symptom burden to evaluate treatment response.

🔍 Is This Medicine Right for Your Symptom?

Educational reference. Always consult a doctor for diagnosis.

✅
Enlarged spleen
This medicine is commonly prescribed to reduce spleen size in myelofibrosis.
Likely Use
✅
Night sweats
This medicine helps relieve night sweats associated with myelofibrosis.
Likely Use
✅
Itching
This medicine can reduce itching in myelofibrosis and polycythemia vera.
Likely Use
❌
Fever
This medicine is not a primary fever reducer and may increase infection risk.
Not Primary
❌
Headache
Headache is a side effect, not an indication for use.
Not Primary

🔬 How This Medicine Works (Pharmacology)

Pharmacokinetics

AbsorptionThis medicine is rapidly absorbed after oral administration, with peak plasma concentrations reached within 1 to 2 hours under fasting conditions. Food does not significantly affect the extent of absorption, but it may delay the time to peak concentration. The absolute bioavailability is not well established but is estimated to be high.
DistributionThis medicine distributes widely into body tissues. It is approximately 97% bound to plasma proteins, primarily albumin. The volume of distribution is not well characterized but is thought to be moderate.
Protein BindingApproximately 97% bound to plasma proteins, mainly albumin.
MetabolismThis medicine is primarily metabolized in the liver, mainly by cytochrome P450 enzymes CYP3A4 and to a lesser extent CYP2C9. The metabolites are inactive or have minimal activity.
Half-LifeThe elimination half-life of this medicine is approximately 3 hours in healthy volunteers, but it may be prolonged in patients with hepatic or renal impairment.
ExcretionThis medicine is excreted mainly in the urine as metabolites, with less than 1% excreted unchanged in the urine. Fecal excretion is minimal.
BioavailabilityThe absolute bioavailability of this medicine is not well established but is estimated to be high, around 80% or more.
Onset of ActionThe onset of action varies depending on the indication. In myelofibrosis, reduction in spleen size may be observed within 2 to 4 weeks, while symptom improvement may occur earlier. In polycythemia vera, effects on blood counts may be seen within 4 to 8 weeks.
Peak Plasma TimePeak plasma concentrations are reached approximately 1 to 2 hours after oral administration under fasting conditions.
Duration of ActionThe duration of action is related to the dosing interval. With twice-daily dosing, the effects are maintained throughout the day. The pharmacodynamic effects persist as long as the drug is present at therapeutic levels.

How It Works

This medicine works by selectively inhibiting Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) enzymes. These enzymes are part of the JAK-STAT signaling pathway, which transmits signals from cytokines and growth factors to the cell nucleus, influencing gene expression. In myelofibrosis and polycythemia vera, abnormal activation of this pathway leads to excessive blood cell production and release of inflammatory cytokines. By blocking JAK1 and JAK2, this medicine reduces the phosphorylation of STAT proteins, thereby decreasing abnormal cell proliferation and inflammation. This results in reduced spleen size and improvement in constitutional symptoms.

Mechanism Steps

1
Binding to JAK enzymes: This medicine binds to the ATP-binding site of JAK1 and JAK2 enzymes, preventing their activation.
2
Inhibition of JAK-STAT signaling: By blocking JAK1 and JAK2, this medicine prevents the phosphorylation and activation of STAT proteins.
3
Reduced gene transcription: Without activated STAT proteins, the transcription of genes involved in cell proliferation and inflammation is decreased.
4
Clinical effects: This leads to reduced spleen size, decreased inflammatory symptoms, and improved blood counts in patients with myelofibrosis or polycythemia vera.

💡 How to Take jakavi 15mg tablet

Strength: 15 mg immediate-release tablet

1Take this medicine exactly as prescribed by your doctor.
2Swallow the tablet whole with a glass of water. Do not crush, chew, or break the tablet.
3You may take this medicine with or without food. However, taking it with food may help reduce stomach upset.
4Take it at the same times each day to maintain consistent blood levels.
5If you miss a dose, follow the missed dose instructions.
6Do not stop taking this medicine without consulting your doctor.
7Avoid grapefruit and grapefruit juice while taking this medicine.

Dosage Information

Adult DosageThe recommended starting dose of this medicine for myelofibrosis is 15 mg or 20 mg orally twice daily, depending on platelet counts. For polycythemia vera, the starting dose is 10 mg twice daily. For graft-versus-host disease, the dose is 5 mg twice daily. Dose adjustments are required based on blood counts, renal and hepatic function, and concomitant medications. Dose must be individualized by a qualified clinician based on indication, age, weight, renal and hepatic function.
Pediatric DosagePediatric dosing is not established from available information. Consult a pediatrician.
Elderly DosageNo specific dose adjustment is recommended for elderly patients based solely on age. However, elderly patients may be more sensitive to the effects of this medicine, particularly myelosuppression and infections. Dose should be individualized based on renal and hepatic function and overall health status.
Renal ImpairmentFor patients with moderate renal impairment (creatinine clearance 30-59 mL/min), the starting dose should be reduced by 50% for myelofibrosis and polycythemia vera. For severe renal impairment (creatinine clearance <30 mL/min), the starting dose should be reduced by 50% and used with caution. Avoid use in patients with end-stage renal disease on dialysis.
Hepatic ImpairmentFor patients with mild or moderate hepatic impairment (Child-Pugh A or B), the starting dose should be reduced by 50% for myelofibrosis and polycythemia vera. This medicine is contraindicated in patients with severe hepatic impairment (Child-Pugh C).
Maximum Daily DoseThe maximum recommended daily dose is 25 mg twice daily for myelofibrosis, but this must be individualized. Do not exceed the dose prescribed by your doctor.

Dosage Timeline

🌅 Morning ❌ ☀️ Afternoon ❌ 🌆 Evening ❌ 🌙 Night ❌

🍽️ Food Timing Guide

With or without food
Take at the same time each day
Food does not significantly affect absorption, but taking it consistently helps maintain blood levels.
Grapefruit and grapefruit juice
Avoid
Grapefruit inhibits CYP3A4, which can increase the levels of this medicine and lead to increased side effects.

⏰ What to Do If You Miss a Dose

📌 Less than half the dosing interval has passed (e.g., less than 6 hours for twice-daily dosing)
→ Take the missed dose as soon as you remember.
💡 Continue with the regular schedule.
📌 More than half the dosing interval has passed (e.g., more than 6 hours for twice-daily dosing)
→ Skip the missed dose.
💡 Do not double dose to catch up. Take the next dose at the regular time.

⚠️ Side Effects of jakavi 15mg tablet

✅ Common Side Effects

Dizziness (Common (10-20%))
Avoid driving or operating machinery until you know how this medicine affects you. If dizziness persists, consult your doctor.
Headache (Common (10-20%))
Rest and stay hydrated. Over-the-counter pain relievers may help, but consult your doctor before taking any new medicine.
Fatigue (Common (10-20%))
Ensure adequate rest and a balanced diet. If fatigue is severe or persistent, inform your doctor.
Anemia (Common (20-30%))
Regular blood tests will monitor your hemoglobin. If you experience shortness of breath or paleness, contact your doctor.
Thrombocytopenia (Common (20-30%))
Report any unusual bruising or bleeding to your doctor immediately. Dose adjustment may be needed.
Neutropenia (Common (10-20%))
Monitor for signs of infection such as fever, sore throat, or chills. Seek medical attention if these occur.

🚨 Serious Side Effects

Severe infections (e.g., tuberculosis, herpes zoster, fungal infections) (Uncommon (1-10%))
Seek immediate medical attention if you develop fever, cough, night sweats, or other signs of infection.
Progressive multifocal leukoencephalopathy (PML) (Rare (<0.1%))
Report any new neurological symptoms such as confusion, memory loss, difficulty walking, or vision changes immediately.
Lymphoma (Rare (<0.1%))
Report any unexplained weight loss, fever, or swollen lymph nodes to your doctor.
Hepatitis B reactivation (Rare (<0.1%))
Your doctor will monitor for hepatitis B before and during treatment. Report yellowing of eyes or skin, dark urine, or abdominal pain.
Severe allergic reactions (anaphylaxis, angioedema) (Rare (<0.1%))
Seek emergency medical help if you experience swelling of face, lips, tongue, or throat, difficulty breathing, or a severe rash.

⚠️ Rare Side Effects

Renal impairment
Regular monitoring of kidney function is required. Report decreased urine output or swelling in legs.
Cardiac arrhythmias
Report palpitations, chest pain, or fainting to your doctor immediately.

Consult your doctor if you experience any unusual symptoms.

🔬 Drug Interactions

Drug Severity Effect
Ketoconazole Major
Rifampin Major
Clarithromycin Major
Warfarin Moderate
Fluconazole Moderate
Phenytoin Major
Carbamazepine Major
Ritonavir Major
Live vaccines Major
Antacids Minor

🚨 Major Interactions

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir)
  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin)
  • Live vaccines

⚡ Moderate Interactions

  • Fluconazole
  • CYP2C9 substrates (e.g., warfarin)

🍷 Alcohol Interaction

Alcohol may increase the risk of dizziness, drowsiness, and liver problems. It is advisable to avoid or limit alcohol consumption while taking this medicine. Consult your doctor for personalized advice.

🔎 Check Your Other Medicines

Educational tool. Always confirm with your doctor or pharmacist.

🛡️ Safety & Warnings

🚫 Contraindications

["Hypersensitivity to ruxolitinib or any component of the formulation.","Severe hepatic impairment (Child-Pugh C).","Severe renal impairment (creatinine clearance

⚠️ Warnings & Precautions

["This medicine can cause serious infections. Monitor for signs and symptoms of infection and treat promptly.","It can cause myelosuppression, including anemia, thrombocytopenia, and neutropenia. Regular blood counts are essential.","Progressive multifocal leukoencephalopathy (PML) has been reported. Monitor for neurological symptoms.","Hepatitis B reactivation can occur. Screen for hepatitis B before starting treatment.","Live vaccines should not be administered during treatment.","Avoid grapefruit and grapefruit juice.","Use effective contraception during treatment and for at least 2 weeks after the last dose.","Do not stop this medicine abruptly without consulting your doctor, as it may cause a flare of symptoms.","This medicine may impair your ability to drive or operate machinery. Avoid these activities until you know how it affects you."]

🤱 Lactation Safety

It is not known whether this medicine passes into breast milk. Because of the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for at least 2 weeks after the last dose. Consult your doctor for alternative feeding options.

💊 Overdose Management

There is no specific antidote for overdose with this medicine. In case of suspected overdose, seek immediate medical attention. Treatment should be supportive and symptomatic. Monitor blood counts and vital signs closely. Hemodialysis is not expected to be effective in removing this medicine from the body.

⏰ Missed Dose

If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time to make up for a missed dose.

Additional Safety Advice

General Safety

This medicine must be taken exactly as prescribed by your doctor. Do not stop or change the dose without consulting your healthcare provider. Regular blood tests are mandatory to monitor blood counts, liver and kidney function. Avoid contact with people who have active infections. Inform your doctor if you have a history of tuberculosis, hepatitis, or shingles. Do not receive live vaccines while on this medicine. Use effective contraception during treatment and for at least 2 weeks after the last dose. Avoid grapefruit and grapefruit juice as it may increase drug levels. If you miss a dose, take it as soon as you remember, but if it is almost time for the next dose, skip the missed dose and continue with your regular schedule. Do not double the dose.

👴 Special Considerations for Elderly

💡 For Patients Above 65

Elderly patients (65 years and older) may be more sensitive to the effects of this medicine, particularly myelosuppression, infections, and cardiovascular events. No dose adjustment is recommended based solely on age, but dose should be individualized based on renal and hepatic function, concomitant medications, and overall health status. Close monitoring is advised.

🤰 Pregnancy Planning (TTC)

This medicine may cause harm to the unborn baby. Women of childbearing potential should use effective contraception during treatment and for at least 2 weeks after the last dose. If you are planning to become pregnant, consult your doctor before stopping or changing your treatment. Your doctor will discuss the risks and benefits and may recommend alternative treatments. Men taking this medicine should also use effective contraception, as it may affect sperm and potentially harm the fetus.

🏥 Post-Surgery Considerations

This medicine can increase the risk of bleeding and infection after surgery. Inform your surgeon and anesthesiologist that you are taking this medicine. Your doctor may recommend temporarily stopping the medicine before surgery, depending on the type of surgery and your overall health. Do not stop the medicine without consulting your doctor. After surgery, monitor for signs of infection and bleeding, and follow your doctor's instructions for resuming treatment.

🦷 Dental Procedures

This medicine can increase the risk of bleeding and infection during dental procedures. Inform your dentist that you are taking this medicine. Your dentist may recommend antibiotics before dental work to prevent infection. Your doctor may also advise temporarily stopping the medicine before dental procedures, but do not stop without consulting your doctor. Maintain good oral hygiene to reduce the risk of infection.

💚 Lifestyle Tips for Better Results

🏃
Maintain a balanced diet rich in fruits, vegetables, and lean proteins to support your immune system.
🥗
Stay well hydrated by drinking plenty of water throughout the day.
😴
Avoid crowded places and people with active infections to reduce the risk of serious infections.
💧
Practice good hand hygiene to prevent infections.
🧘
Get adequate rest and sleep to help your body cope with treatment.
🌞
Engage in light to moderate exercise as tolerated to maintain strength and well-being.
🚭
Avoid alcohol as it may increase the risk of liver problems and dizziness.
🥑
Keep all follow-up appointments and blood tests to monitor your progress.

🏋️ Exercise Considerations

This medicine may cause fatigue, dizziness, and low blood counts, which can affect your ability to exercise. Avoid strenuous activities until you know how this medicine affects you. Light to moderate exercise, such as walking or yoga, may be beneficial, but consult your doctor before starting any exercise program. If you experience shortness of breath, chest pain, or severe fatigue during exercise, stop and seek medical attention.

🥗 Diet Recommendations

Include foods rich in iron and vitamin B12 to help prevent anemia, such as lean meats, leafy greens, and fortified cereals.
Eat a variety of fruits and vegetables to support your immune system.
Avoid grapefruit and grapefruit juice as they can interact with this medicine.
Limit processed foods, sugary drinks, and high-fat meals to maintain overall health.
Stay well hydrated by drinking water and other fluids throughout the day.
If you have a poor appetite, eat small, frequent meals and consult a nutritionist.

💼 Impact on Daily Work & Life

This medicine can cause fatigue, dizziness, and low blood counts, which may affect your ability to work and perform daily activities. Avoid driving or operating heavy machinery until you know how this medicine affects you. You may need to take time off for medical appointments and blood tests. Discuss your work schedule and any necessary accommodations with your employer. It is important to balance rest and activity to manage fatigue.

🛑 When to Stop This Medicine

Do not stop taking this medicine without consulting your doctor. Your doctor may decide to stop treatment if you experience severe side effects, if the disease progresses, or if you do not respond to treatment. If you need to stop, your doctor will provide instructions on how to taper the dose to avoid a flare of symptoms. Always consult your healthcare provider before making any changes to your treatment.

📅 Long-Term Use Effects

Long-term use of this medicine may lead to persistent myelosuppression, increasing the risk of anemia, thrombocytopenia, and neutropenia. There is also a risk of serious infections, lymphoma, and cardiovascular events. Regular monitoring of blood counts, liver and kidney function, and clinical symptoms is essential. Patients should be evaluated periodically for any new or worsening symptoms. The long-term safety profile is still being studied, and patients should remain under close medical supervision.

🌿 Non-Medicine Approaches

These can complement medicine but do not replace prescribed treatment.

Clinical trials

Participation in clinical trials may provide access to new treatments for myelofibrosis or polycythemia vera.

Evidence: Varies
Stem cell transplant

Allogeneic stem cell transplant is the only potential cure for myelofibrosis and may be considered for eligible patients.

Evidence: Well-established
Supportive care

Blood transfusions, erythropoietin-stimulating agents, and other supportive measures can help manage symptoms and complications.

Evidence: Well-established

💉 Vaccination Considerations

💉 If You're Getting Vaccinated

Live vaccines should not be administered during treatment with this medicine due to the risk of vaccine-related infections. Inactivated vaccines may be given, but their effectiveness may be reduced due to immunosuppression. Consult your doctor before receiving any vaccine. It is recommended to complete all necessary vaccinations before starting this medicine, if possible.

📦 Storage Guide

✅ DO

Store at room temperature between 20°C and 25°C (68°F to 77°F).

❌ DON'T

Do not refrigerate or freeze.

✅ DO

Keep in the original container, tightly closed.

❌ DON'T

Do not transfer to unmarked containers.

✅ DO

Keep away from direct sunlight and moisture.

❌ DON'T

Do not store in the bathroom.

✅ DO

Keep out of reach of children and pets.

❌ DON'T

Do not use after the expiry date.

✈️ Traveling with This Medicine

When traveling, carry this medicine in its original packaging with the prescription label. Bring a copy of your prescription and a doctor&#039;s note explaining your medical condition and the need for this medicine. Keep it in your carry-on luggage to avoid loss or temperature extremes. Store at room temperature, away from direct sunlight and moisture. If crossing time zones, adjust dosing times gradually in consultation with your doctor. Check local customs regulations for controlled substances, though this medicine is not typically a controlled substance. Always carry enough supply for the entire trip plus extra in case of delays.

💰 Cost Analysis & Savings

👥 Real Patient Stories

Educational, anonymized scenarios. Individual results may vary.

👤 A 62-year-old man with primary myelofibrosis
He started this medicine at 15 mg twice daily. After 4 weeks, his spleen size reduced significantly, and his night sweats and itching improved. He experienced mild dizziness initially, which resolved after a few days. Regular blood tests showed a slight drop in hemoglobin, but it stabilized with dose adjustment. He emphasizes the importance of taking the medicine at the same time every day and attending all follow-up visits.
💡 Lesson: Consistent dosing and regular monitoring are key to managing myelofibrosis effectively with this medicine.
👤 A 55-year-old woman with polycythemia vera resistant to hydroxyurea
She was switched to this medicine at 10 mg twice daily. Her hematocrit levels normalized within 8 weeks, and her fatigue improved. She had an episode of shingles, which was treated promptly. She advises other patients to report any new symptoms immediately and to avoid grapefruit juice as instructed by her doctor.
💡 Lesson: This medicine can be effective in polycythemia vera, but patients must be vigilant about infections and adhere to dietary restrictions.

💬 Questions Patients Often Ask

Q: How long does it take to work?

A: Improvement in symptoms such as night sweats and itching may be noticed within 2 to 4 weeks. Reduction in spleen size may take 4 to 8 weeks. However, the full benefits may take several months. Regular follow-up with your doctor is important to assess response.

Q: Can I take this medicine with food?

A: Yes, you can take this medicine with or without food. Taking it with food may help reduce stomach upset. However, avoid grapefruit and grapefruit juice as they can increase the levels of this medicine.

Q: What should I do if I miss a dose?

A: If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time.

Q: Is this medicine safe during pregnancy?

A: This medicine may harm the unborn baby. It is not recommended during pregnancy. Women of childbearing potential should use effective contraception during treatment and for at least 2 weeks after the last dose. Consult your doctor if you are pregnant or planning to become pregnant.

Q: Can I stop taking this medicine if I feel better?

A: No, do not stop taking this medicine without consulting your doctor. Stopping abruptly can cause a flare of symptoms. Your doctor will decide if and when to discontinue treatment.

🤔 Common Patient Concerns

💭 These are the concerns patients most commonly raise

  • Can I take this medicine long-term?
  • Will it affect my kidney function?
  • Can I drive after taking this medicine?
  • Does it interact with my blood pressure medicine?
  • What if I miss a dose?
  • Can I drink alcohol while taking this?
  • Is it safe to take during pregnancy?
  • What are the signs of infection I should watch for?

🛑 Myths vs. Facts

  • Myth: This medicine can cure myelofibrosis.
    Fact: This medicine does not cure myelofibrosis but helps manage symptoms and reduce spleen size. It is a chronic treatment.
  • Myth: This medicine is safe to take without regular blood tests.
    Fact: Regular blood tests are essential to monitor for serious side effects such as low blood counts and liver problems.
  • Myth: You can stop taking this medicine once you feel better.
    Fact: Do not stop this medicine without consulting your doctor. Stopping abruptly can cause a flare of symptoms.

🔄 Alternative Options

Brand Alternatives

📊 Comparison with Similar Medicines

[{"medicine":"This medicine","class":"JAK1/JAK2 inhibitor","primary_use":"Myelofibrosis, Polycythemia Vera, GVHD","route":"Oral","half_life":"3 hours"},{"medicine":"Fedratinib","class":"JAK2 inhibitor","primary_use":"Myelofibrosis","route":"Oral","half_life":"Not established"},{"medicine":"Pacritinib","class":"JAK2/FLT3 inhibitor","primary_use":"Myelofibrosis","route":"Oral","half_life":"Not established"}]

😊 Was this information helpful?

Browse Medicines A-Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Back to Medicines Directory